HanAll Biopharma
VC Fund
Seoul, South Korea
HanAll Biopharma is a VC fund in Seoul focused on Biotechnology and Health Care. HanAll Biopharma is World’s Best Bio Pharma for R&D of New Innovative Medicine Respectful Pharmaceutical Company to Contribute to Health of the World and to Lead Health Improvement of Mankind.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries HanAll Biopharma invests in
Stages HanAll Biopharma invests in
Countries HanAll Biopharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Almira Chabi
|
|||
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Medical 2 (33%)
- Genetics 1 (17%)
- Biopharma 1 (17%)
Stage
- Corporate Round 3 (50%)
- Series A 2 (33%)
- Venture - Series Unknown 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Almira Chabi
Chief Medical Officer and Chief Development Officer
|
Chief Medical Officer and Chief Development Officer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | |
|
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $2M / Corporate Round / Jun 12, 2023 | |
Interon
|
Interon Laboratories is developing a new category of immunotherapy for neuro-immunotherapy. | Corporate Round / Feb 02, 2023 | |
Turn.bio
|
Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells. | Venture - Series Unknown / Apr 11, 2022 | |
Alloplex Biotherapeutics
|
Alloplex Biotherapeutics is a privately held Boston based cellular therapeutics company. Their lead oncology therapeutic is a PBMC-derived multicellular adoptive immunotherapy which they call SUPLEXA cells. They use proprietary leukocyte activator cell lines (ENLiST cells), which are engineered from a common tumor cell line to express an array ofimmunomodulatory ligands designed to specifically engage and activate various subsets of peripheral blood mononuclear cells (PBMC) through their native receptors. Alloplex has developed SUPLEXA cells through the use of an all-human in vitro assay which not only models the intended ex vivo activation of patient PBMC but is, in fact, the actual procedure to be deployed in the clinic. The company was founded in 2016 and is headquartered in Boston, Massachusetts. | $1M / Corporate Round / Aug 19, 2021 | |
NurrOn Pharmaceuticals
|
NurrOn Pharmaceuticals operates as an innovative pharmaceutical company. | Series A / Jan 01, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does HanAll Biopharma invest in?
HanAll Biopharma invests primarily in Biotechnology, Health Care and Medical startups, most often at Corporate Round and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact HanAll Biopharma?
Public channels for HanAll Biopharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HanAll Biopharma?
The team at HanAll Biopharma includes Almira Chabi (Chief Medical Officer and Chief Development Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
